MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price hit a new 52-week low on Friday . The company traded as low as GBX 275 ($3.44) and last traded at GBX 275 ($3.44), with a volume of 61486 shares traded. The stock had previously closed at GBX 285 ($3.57).
MaxCyte Price Performance
The company has a quick ratio of 14.38, a current ratio of 17.92 and a debt-to-equity ratio of 6.72. The business has a 50-day moving average price of GBX 325.58 and a two-hundred day moving average price of GBX 350.37. The company has a market capitalization of £292.39 million, a price-to-earnings ratio of -1,130.00 and a beta of 0.78.
Insider Transactions at MaxCyte
In other news, insider John Johnston sold 118 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of GBX 480 ($6.01), for a total transaction of £566.40 ($708.80). 1.19% of the stock is owned by insiders.
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
- Five stocks we like better than MaxCyte
- How Can Investors Benefit From After-Hours Trading
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- What Are Defense Contractor Stocks? How to Invest in Defense
- MarketBeat Week in Review – 9/11 – 9/15
- How to Invest in Electric Cars
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.